270 related articles for article (PubMed ID: 32494661)
1. Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy.
Noman MZ; Parpal S; Van Moer K; Xiao M; Yu Y; Viklund J; De Milito A; Hasmim M; Andersson M; Amaravadi RK; Martinsson J; Berchem G; Janji B
Sci Adv; 2020 May; 6(18):eaax7881. PubMed ID: 32494661
[TBL] [Abstract][Full Text] [Related]
2. Lighting up the fire in cold tumors to improve cancer immunotherapy by blocking the activity of the autophagy-related protein PIK3C3/VPS34.
Janji B; Hasmim M; Parpal S; De Milito A; Berchem G; Noman MZ
Autophagy; 2020 Nov; 16(11):2110-2111. PubMed ID: 32892693
[TBL] [Abstract][Full Text] [Related]
3. Firing up the cold tumors by targeting Vps34.
Janji B; Hasmim M; Parpal S; Berchem G; Noman MZ
Oncoimmunology; 2020 Aug; 9(1):1809936. PubMed ID: 32939326
[TBL] [Abstract][Full Text] [Related]
4. A Novel Tri-Functional Liposome Re-Educates "Cold Tumor" and Abrogates Tumor Growth by Synergizing Autophagy Inhibition and PD-L1 Blockade.
Zhou F; Li X; Xue X; Li S; Fan G; Cai Y; Chang Z; Qu J; Liu R
Adv Healthc Mater; 2023 Apr; 12(11):e2202757. PubMed ID: 36652763
[TBL] [Abstract][Full Text] [Related]
5. Erratum for the Research Article: "Inhibition of Vps34 reprograms cold into hot inflamed tumors and improves anti-PD-1/PD-L1 immunotherapy".
Sci Adv; 2021 Apr; 7(15):. PubMed ID: 33837089
[No Abstract] [Full Text] [Related]
6. Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance.
Zheng W; Skowron KB; Namm JP; Burnette B; Fernandez C; Arina A; Liang H; Spiotto MT; Posner MC; Fu YX; Weichselbaum RR
Oncotarget; 2016 Jul; 7(28):43039-43051. PubMed ID: 27343548
[TBL] [Abstract][Full Text] [Related]
7. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
8. Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity.
Sam J; Colombetti S; Fauti T; Roller A; Biehl M; Fahrni L; Nicolini V; Perro M; Nayak T; Bommer E; Schoenle A; Karagianni M; Le Clech M; Steinhoff N; Klein C; Umaña P; Bacac M
Front Oncol; 2020; 10():575737. PubMed ID: 33330050
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral injection of IFN-β induces chemokine production in melanoma and augments the therapeutic efficacy of anti-PD-L1 mAb.
Uehara J; Ohkuri T; Kosaka A; Ishibashi K; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Ishida-Yamamoto A; Kobayashi H
Biochem Biophys Res Commun; 2017 Aug; 490(2):521-527. PubMed ID: 28624449
[TBL] [Abstract][Full Text] [Related]
10. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
11. Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis.
Sun M; Gu P; Yang Y; Yu L; Jiang Z; Li J; Le Y; Chen Y; Ba Q; Wang H
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34117115
[TBL] [Abstract][Full Text] [Related]
12. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
Li J; Xu J; Yan X; Jin K; Li W; Zhang R
Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
[TBL] [Abstract][Full Text] [Related]
13. Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy.
Lequeux A; Noman MZ; Xiao M; Van Moer K; Hasmim M; Benoit A; Bosseler M; Viry E; Arakelian T; Berchem G; Chouaib S; Janji B
Oncogene; 2021 Jul; 40(28):4725-4735. PubMed ID: 34155342
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms involved in IL-15 superagonist enhancement of anti-PD-L1 therapy.
Knudson KM; Hicks KC; Alter S; Schlom J; Gameiro SR
J Immunother Cancer; 2019 Mar; 7(1):82. PubMed ID: 30898149
[TBL] [Abstract][Full Text] [Related]
15. "Suffocating" tumors by blocking adaptation to hypoxia: a new headway in melanoma immunotherapy.
Janji B; Chouaib S
Oncoimmunology; 2021; 10(1):1968611. PubMed ID: 34527430
[TBL] [Abstract][Full Text] [Related]
16. Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment.
Lim YW; Coles GL; Sandhu SK; Johnson DS; Adler AS; Stone EL
BMC Biol; 2021 May; 19(1):107. PubMed ID: 34030676
[TBL] [Abstract][Full Text] [Related]
17. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
18. Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity.
Li L; Yang L; Cheng S; Fan Z; Shen Z; Xue W; Zheng Y; Li F; Wang D; Zhang K; Lian J; Wang D; Zhu Z; Zhao J; Zhang Y
Mol Cancer; 2019 Jun; 18(1):108. PubMed ID: 31221150
[TBL] [Abstract][Full Text] [Related]
19. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
20. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
[Next] [New Search]
